Prabhudas Lilladher Recommends Buying Torrent Pharmaceuticals, Sets Rs 5,500 Target
Prabhudas Lilladher’s report says Torrent Pharma’s Q2FY27 performance was in line, with base-business EBITDA growing 20% year over year, driven by domestic franchise momentum. The report also mentions injectable semaglutide.